AFYA Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
Afya Ltd is not a strong buy for a beginner investor with a long-term strategy at this time. The stock lacks significant positive catalysts, has been downgraded by multiple analysts, and faces near-term margin pressures due to rising investments in non-core businesses. While the company's financials show growth in revenue and net income, the gross margin decline and lack of strong trading signals suggest a cautious approach. Holding the stock may be more prudent until clearer positive trends emerge.
The MACD is positive but contracting, RSI is neutral at 58.283, and moving averages are converging, indicating no clear trend. The stock is trading near its first resistance level (R1: 15.406) but lacks momentum for a breakout.
Revenue and net income have shown YoY growth in the latest quarter, with EPS increasing by 15.15%.
Multiple analyst downgrades citing margin pressures, slower volume growth, and rising investments in non-core businesses. Gross margin dropped by 3.15% YoY. No recent news or significant trading trends from hedge funds or insiders.
In Q4 2025, revenue increased by 7.54% YoY to 912.99M, net income rose by 15.36% YoY to 172.96M, and EPS grew by 15.15% YoY to 1.9. However, gross margin declined by 3.15% YoY to 61.81.
Recent analyst downgrades from BofA, Morgan Stanley, BTG Pactual, UBS, and JPMorgan, with price targets lowered to a range of $16-$22. Analysts cite margin pressures, slower growth, and higher investments as key concerns.
